Report cover image

Herceptin Biosimilar Market, by Indication (Breast Cancer, Gastric Cancer, and Others), by Distribution Channel (Hospital, Oncology Centers, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Sh

Publisher Coherent Market Insights
Published May 26, 2022
Length 175 Pages
SKU # CMI17212669

Description

Herceptin Biosimilar Market, by Indication (Breast Cancer, Gastric Cancer, and Others), by Distribution Channel (Hospital, Oncology Centers, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Trastuzumab, sold under the brand Herceptin, is a monoclonal antibody used for the treatment of breast cancer and gastric cancer. Herceptin is mainly used to treat patients suffering from cancer and diagnosed with HER2 receptor positive. Herceptin mechanism of action is binding itself to HER2 receptors on the surface of breast cancer cells and blocking them from receiving growth signals and thus decreasing the mutation of cells. Herceptin acts as an immune targeted therapy for breast cancer patients.
Market Dynamics
Product approvals and launches are the factors driving the growth of the global herceptin biosimilar market. For instance, in February 2020, Pfizer Inc., a biotechnology and pharmaceutical company in the U.S., launched the trastuzumab biosimilar, Trazimera, for treatment of human epidermal growth receptor causing breast cancer and metastatic gastric cancer.
Key features of the study:
This report provides in-depth analysis of the global herceptin biosimilar market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global Herceptin biosimilar market based on the following parameters – company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study are Amgen Inc., AryoGen Biopharma, Biocon Limited, Celltrion Inc., Pfizer Inc., Merck & Co., Inc., Accord Healthcare Ltd, Gedeon Richter Plc, Genor Biopharma Company Ltd, Mabion SA, Mylan N.V, Roche Holding AG and Samsungbioepis Co,.Ltd
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
The global herceptin biosimilar market report caters to various stakeholders in this industry including investors, suppliers, device manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global herceptin biosimilar market.
Detailed Segmentation:
Global Herceptin Biosimilar Market, By Indication:
Breast Cancer
Gastric Cancer
Others
Global Herceptin Biosimilar Market, By Distribution Channel :
Hospitals
Oncology Centers
Others
Global Herceptin Biosimilar Market, By Region:
North America
By Indication:
Breast Cancer
Gastric Cancer
Others
By Distribution Channel :
Hospital
Oncology Centers
Others
By Country:
U.S.
Canada
Latin America
By Indication:
Breast Cancer
Gastric Cancer
Others
By Distribution Channel :
Hospital
Oncology Centers
Others
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Indication:
Breast Cancer
Gastric Cancer
Others
By Distribution Channel :
Hospital
Oncology Centers
Others
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Indication:
Breast Cancer
Gastric Cancer
Others
By Distribution Channel :
Hospital
Oncology Centers
Others
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Indication:
Breast Cancer
Gastric Cancer
Others
By Distribution Channel :
Hospital
Oncology Centers
Others
By Country/Region:
GCC
Israel
Rest of Middle East
Africa
By Indication:
Breast Cancer
Gastric Cancer
Others
By Distribution Channel :
Hospital
Oncology Centers
Others
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Amgen Inc. *
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
AryoGen Biopharma
Biocon Limited
Celltrion Inc.
Pfizer Inc.
Merck & Co., Inc.
Accord Healthcare Ltd.
Gedeon Richter Plc.
Genor Biopharma Company Ltd
Mabion SA
Mylan N.V.
Roche Holding AG
Samsungbioepis Co,.Ltd

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

175 Pages
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Indication
Market Snippet, By Distribution Channel
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Impact Analysis
Market Opportunities
Regulatory Scenario
Recent Product Approval/ Launch
Key Development
PEST Analysis
Epidemiology
Mergers and Acquisitions
Value Chain Analysis
4. Global Herceptin Biosimilar Market, Impact of COVID-19 Pandemic
Post COVID-19 Impact
Demand and Supply Chain Analysis
Government Initiative
5. Global Herceptin Biosimilar Market, By Indication, 2017 - 2028 (US$ Mn)
Introduction
Market Share Analysis, 2022 and 2028 (%)
Y-o-Y Growth Analysis, 2017 - 2028
Segment Trends
Breast Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Gastric Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
6. Global Herceptin Biosimilar Market, By Distribution Channel, 2017 - 2028 (US$ Mn)
Introduction
Market Share Analysis, 2022 and 2028 (%)
Y-o-Y Growth Analysis, 2017 - 2028
Segment Trends
Hospitals
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Oncology Centers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
7. Global Herceptin Biosimilar Market, By Region, 2017 - 2028 (US$ Mn)
Introduction
Market Share Analysis, By Region, 2022 and 2028 (%)
Y-o-Y Growth Analysis, For Countries, 2017 - 2028
North America
Introduction
Market Size and Forecast, By Indication , 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
U.S.
Canada
Latin America
Introduction
Market Size and Forecast, By Indication , 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Introduction
Market Size and Forecast, By Indication , 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, By Indication , 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
Introduction
Market Size and Forecast, By Indication , 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, By Indication , 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
South Africa
Central Africa
North Africa
8. Competitive Landscape
Company Profiles
Amgen Inc.
Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies
AryoGen Biopharma
Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies
Biocon Limited
Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies
Celltrion Inc.
Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies
Pfizer Inc.
Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies
Merck & Co., Inc.
Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies
Accord Healthcare Ltd.
Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies
Gedeon Richter Plc.
Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies
Genor Biopharma Company Ltd
Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies
Mabion SA
Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies
Mylan N.V.
Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies
Market Strategies
Roche Holding AG
Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies
Market Strategies
Samsungbioepis Co,.Ltd
Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies
Market Strategies
*Browse 33 market data tables and 32 figures on "Herceptin Biosimilar Market– Global forecast to 2028”.

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us